Kither Biotech
Heikki Lanckriet's work experience includes roles at multiple companies. Heikki served as a Non Executive Director at Kither Biotech since March 2022 and at NeoPhore Ltd since March 2021. Prior to that, they were the Chief Executive Officer at 4basebio starting from January 2020. Heikki also held various roles at Expedeon, including CEO from July 2016 to January 2020, CEO from October 2008 to January 2020, and CSO from May 2004 to October 2008. Heikki Lanckriet's earlier work experience includes a role as Research Manager at Puratos in 2000.
Heikki Lanckriet pursued their education with utmost dedication and achieved significant milestones. Heikki Lanckriet completed their Master's degree in Bio-Ingenieur from Ghent University between 1995 and 2000. Following this, they pursued a PhD in Chemical Engineering at the University of Cambridge from 2001 to 2004. These educational experiences have equipped Heikki Lanckriet with a strong foundation in both bio-ingenieur and chemical engineering, providing him with a diverse skill set in these fields.
This person is not in any teams
This person is not in any offices
Kither Biotech
Kither Biotech is a pharmaceutical product company that focuses its R&D activities on the development of new drugs. The R&D activities of the company mainly involve the development of new drugs to treat chronic inflammatory diseases.In recent years Kither has focused its first line of activities on the development of a small peptide(KIT2014) developed internally for the treatment of cystic fibrosis, a disease that predominantly affects the lungs and that currently has no cure. The KIT2014 peptide was assigned the Orphan Drug designation from the European Medicines Agency. The KIT2014 compound is currently undergoing the pre-clinical phase of clinical development.Kither’s product portfolio also includes a molecule (CL27), also developed internally, that is being developed for the treatment of Chronic Obstructive Pulmonary Diseases and Allergic Asthma. The company is about to start the pre-clinical phase of development of the CL27 molecule.